Before Heptares was founded, the only resolved X-ray crystallography structure of a GPCR was rhodopsin. Other proteins, such as kinases, crystalize more readily, allowing chemists to employ ...

On Monday, Leerink Partners adjusted its price target for Structure Therapeutics (NASDAQ:GPCR) shares, reducing it to $60 from the ...

(NASDA SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule ...

Find the latest Structure Therapeutics Inc. GPCR analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned a consensus rating of “Buy” from the eight research firms that are covering the company, MarketBeat ...

Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

M&T Bank Corp raised its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 100.0% during the 4th quarter ...

In trading on Wednesday, shares of Structure Therapeutics Inc (Symbol: GPCR) entered into oversold territory, hitting an RSI reading of 29.0, after changing hands as low as $19.61 per share.